Combined serum biomarkers in non-invasive diagnosis of non-alcoholic steatohepatitis

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Yang, Mei ^a   Xu, Dongping ^a   Liu, Yuan ^a   Guo, Xiaodong ^a   Li, Wenshu ^a   Guo, Chaonan ^a   Zhang, Hongping ^a   Gao, Yinjie ^a   Mao, Yuanli ^a   Zhao, Jingmin ^a  

^a BEIJING 302 HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOKERATIN 18; CYTOKERATIN 18 M30 FRAGMENT; FIBROBLAST GROWTH FACTOR 21; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; OSTEOPROTEGERIN; PIGMENT EPITHELIUM DERIVED FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; BLOOD; CASE CONTROL STUDY; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY; STATISTICAL MODEL;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; NUCLEOPOLYHEDROVIRUS;

ADULT; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84938696564     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131664     Document Type: Article

References (53)

1. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003; 98: 960-967. PMID: 12809815
2. Kim WR, Brown RSJ, Terrault NA, EI-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002; 36: 227-242. PMID: 12085369
3. Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004; 126: 586-597. PMID: 14762795
4. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohep-atitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011; 140: 124-131. doi: 10.1053/j.gastro.2010.09.038 PMID: 20858492
5. Farrell GC, Wong VW, Chitturi S. NAFLD in Asia - as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013; 10: 307-318. doi: 10.1038/nrgastro.2013.34 PMID: 23458891
6. Lonardo A, Sookoian S, Chonchol M, Loria P, Targher G. Cardiovascular and Systemic Risk in Nonalcoholic Fatty Liver Disease-Atherosclerosis As a Major Player in the Natural Course of NAFLD. Curr Pharm Des. 2013; 19: 5177-5192. PMID: 23432668
7. Musso G, Anty R, Petta S. Antioxidant Therapy and Drugs Interfering with Lipid Metabolism: Could They Be Effective in NAFLD Patients? Curr Pharm Des. 2013; 19: 5297-5313. PMID: 23394094
8. Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes. 2012: 483135. doi: 10.1155/2012/ 483135 Epub 2012 Dec 23. PMID: 23320150
9. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology. 1998; 114: 842-845. PMID: 9547102
10. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43: S99-S112. PMID: 16447287
11. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc. 2000; 75: 733-739. PMID: 10907390
12. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116: 1413-1419. PMID: 10348825
13. Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009; 9: 299-314. PMID: 19355912
14. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcholic fatty liver disease. Curr Opin Gastroenterol. 2008; 24: 320-327. doi: 10.1097/MOG.0b013e3282fbccf2 PMID: 18408460
15. Kashi MR, Torres DM, Harrison SA. Current and emerging therapies in nonalcoholic fatty liver disease. Semin Liver Dis. 2008; 28: 396-406. doi: 10.1055/s-0028-1091984 PMID: 18956296
16. Bianchi L. Liver biopsy in elevated liver function tests? An old question revisited. J Hepatol. 2001; 35: 290-294. PMID: 11580154
17. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009; 50: 1072-1078. doi: 10.1002/hep.23050 PMID: 19585618
18. Lebensztejn DM, Wierzbicka A, Socha P, Pronicki M, Skiba E, Werpachowska I, et al. Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease. Acta Biochim Pol. 2011; 58: 563-566. PMID: 22140659
19. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006; 44: 27-33. PMID: 16799979
20. Fitzpatrick E, Mitry RR, Quaglia A, Hussain MJ, DeBruyne R, Dhawan A. Serum levels of CK18 M30 and leptin are useful predictors of steatohepatitis and fibrosis in paediatric NAFLD. J Pediatr Gastroenterol Nutr. 2010; 51: 500-506. doi: 10.1097/MPG.0b013e3181e376be PMID: 20808246
21. Vos MB, Barve S, Joshi-Barver S, Carew JD, Whitington PF, McClain CJ. Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. J Pediater Gastroenterol Nutr. 2008; 47: 481-485.
22. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, Chen Y, et al. Fibroblast growth factor 21 corrects obesity in mice. Endocrinology. 2008; 149: 6018-6027. doi: 10.1210/en.2008-0816 PMID: 18687777
23. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2009; 58: 250-259. doi: 10.2337/db08-0392 PMID: 18840786
24. Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, et al. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J Clin Invest. 2012; 122: 3476-3489. doi: 10.1172/JCI60777 PMID: 22945633
25. Chen C, Tso AW, Law LS, Cheung BM, Ong KL, Wat NM, et al. Plasma Level of Pigment Epithelium-Derived Factor Is Independently Associatedwith the Development of the Metabolic Syndrome in Chinese Men: A 10-YearProspective Study. J Clin Endocrinol Metab. 2010; 95: 5074-5081. doi: 10.1210/jc.2010-0727 PMID: 20685859
26. Yilmaz Y, Eren F, Ayyildia T, Colak Y, Kurt R, Senates E, et al. Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. Clinica Chimica Acta. 2011; 412: 2296-2299.
27. Yilmaz Y, Eren F. Identification of a support vector machine-based biomarker panel with high sensitivity and specificity for nonalcoholic steatohepatitis. Clin Chim Acta. 2012; 414:154-157. doi: 10.1016/j.cca.2012.08.005 PMID: 22985537
28. Mao T, Gao L, Li H, Li J. Pigment epithelium-derived factor inhibits high glucose induced oxidative stress and fibrosis of cultured human glomerular mesangial cells. Saudi Med J. 2011; 32: 769-777. PMID: 21858384
29. An JJ, Han DH, Kim DM, Kim SH, Rhee Y, Lee EJ, et al. Expression and regulation of osteoprotegerin in adipose tissue. Yonsei Med J. 2007; 48: 765-772. PMID: 17963332
30. Tamimi TI, Elgouhari HM, Alkhouri N, Yerian LM, Berk MP, Lopez R, et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol. 2011; 54: 1224-1229. doi: 10.1016/j.jhep.2010.08.023 PMID: 21145805
31. Bell LN, Theodorakis JL, Vuppalanchi R, Saxena R, Bemis KG, Wang M, et al. Serum proteomics and biomarker discovery across the spectrum of nonal-coholic fatty liver disease. Hepatology. 2010; 51: 111-120. doi: 10.1002/hep.23271 PMID: 19885878
32. Liver Disease and Metabolic Disorders Research Group (preparing), Chinese Society of Endocrinology. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders. Clin J Endocrinol Metab. 2010; 26: 531-534. (in Chinese)
33. Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association. Guidelines for diagnosis and treatment of alcoholic liver disease. Zhonghua Ganzangbing Zazhi. 2006; 14:164-166. (in Chinese) PMID: 16700134
34. Sherman M, Shafran S, Burak K, Doucette K, Wong W, Girgrah N, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol. 2007; 21: 5C-24C. PMID: 17568823
35. Alberti A, Benvegnu L. Management of hepatitis C. J Hepatol. 2003; 38: S1014-S118.
36. Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010; 59: 969-974. doi: 10.1136/gut.2009.205088 PMID: 20581244
37. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313-1321. PMID: 15915461
38. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. 1999; 116: 1413-1419. PMID: 10348825
39. Sanyal AJ, Brunt EM, Kleiner DE, Kowdley KV, Chalasani N, Lavine JE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology. 2011; 54: 344-353. doi: 10.1002/hep.24376 PMID: 21520200
40. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology. 2009; 50: 1072-1078. doi: 10.1002/hep.23050 PMID: 19585618
41. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010; 139: 456-463. doi: 10.1053/j.gastro.2010.04.054 PMID: 20451522
42. Yilmaz Y, Yonal O, Kurt R, Oral AY, Eren F, Ozdogan O, et al. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. Scand J Clin Lab Invest. 2010; 70: 541-546. doi: 10.3109/00365513.2010.524933 PMID: 20942739
43. Pihlajamäki J, Kuulasmaa T, Kaminska D, Dimonen M, Kärjä V, Grönlund S, et al. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol. 2012; 56: 663-670. doi: 10.1016/j.jhep.2011.10.005 PMID: 22027586
44. Gürgen S, Yücel A, Karakuş A, Ceçen D, Ozen G, Koçtürk S. Usage of whey protein may cause liver damage via inflammatory and apoptotic responses. Hum Exp Toxicol. 2014 Oct 28. pii: 0960327114556787.
45. Tabuchi M, Tomioka K, Kawakami T, Murakami Y, Hiramatsu M, Itoshima T, et al. Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD). J Nutr Sci Vitaminol. 2010; 56: 271-278. PMID: 21228496
46. Younossi ZM, Jarrar M, Nugent C, Randhawa M, Afendy M, Stepanova M, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008; 18: 1430-1437. doi: 10.1007/s11695-008-9506-y PMID: 18500507
47. Szalay F, Hegedus D, Lakatos PL, Tornai I, Bajnok E, Dunkel K, et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. J Hepatol. 2003; 38: 395-400. PMID: 12663228
48. Yamagishi SI, Matsui T, Kawaguchi T, Sata M. Pathophysiological role of pigment epithelium-derived factor (PEDF) in hepatic disorders. Curr Med Chem. 2010; 17: 1995-2000. PMID: 20423314
49. Dushay J, Chui PC, Gopalakrishnan GS, Varela-Rey M, Crawley M, Fisher FM, et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology. 2010; 139: 456-463. doi: 10.1053/j.gastro.2010.04.054 PMID: 20451522
50. Yilmaz Y. non-alcoholic fatty liver disease and osteoporosis - clinical and molecular crosstalk. Aliment Pharmacol Ther. 2012; 36: 345-52. doi: 10.1111/j.1365-2036.2012.05196.x PMID: 22730920
51. Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab. 2002; 87: 1184-1188. PMID: 11889184
52. Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002; 36: 986-992. PMID: 12297848
53. Shen J, Chan HL, Wong GL, Choi PC, Chan AW, Chan HY, et al. Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol. 2012; 56: 1363-1370. doi: 10.1016/j.jhep.2011.12.025 PMID: 22314419